Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10154551 | 0.84 | BACE1 (0.40) | BACE1 | |
| SCHEMBL10154568 | 0.84 | BACE1 (0.39) | BACE1 | |
| SCHEMBL14980730 | 0.83 | BACE1 (0.37) | BACE1 | |
| SCHEMBL10154482 | 0.83 | BACE1 (0.47) | BACE1 | |
| SCHEMBL17635530 | 0.83 | BACE1 (0.37) | BACE1 | |
| SCHEMBL13306292 | 0.82 | BACE1 (0.59) | BACE1 | |
| SCHEMBL4074208 | 0.80 | BACE1 (0.48) | BACE1 | |
| SCHEMBL4078345 | 0.80 | BACE1 (0.38) | BACE1 | |
| SCHEMBL10154545 | 0.80 | BACE1 (0.48) | BACE1 | |
| SCHEMBL4078989 | 0.73 | BACE1 (0.52) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653067-B2 | Pharmaceutical composition for treating Alzheimer's disease | SHIONOGI & CO., LTD. (JP) | 2014-02-18 | — | — | US | disclosed |
| US-20100160290-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING ALZHEIMER'S DISEASE | SHIONOGI & CO., LTD. (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20090082560-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160290-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING ALZHEIMER'S DISEASE | NR1H2, NR1H3, NR0B1 | BACE1 14/4885 |
| US-20090082560-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | BACE1, BACE2, APP | BACE1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.